Enhancer activation from transposable elements in extrachromosomal DNA
- PMID: 41120733
- PMCID: PMC12611757
- DOI: 10.1038/s41556-025-01788-6
Enhancer activation from transposable elements in extrachromosomal DNA
Abstract
Extrachromosomal DNA (ecDNA) drives oncogene amplification and intratumoural heterogeneity in aggressive cancers. While transposable element reactivation is common in cancer, its role on ecDNA remains unexplored. Here we map the 3D architecture of MYC-amplified ecDNA in colorectal cancer cells and identify 68 ecDNA-interacting elements-genomic loci enriched for transposable elements that are frequently integrated onto ecDNA. We focus on an L1M4a1#LINE/L1 fragment co-amplified with MYC, which functions only in the ecDNA-amplified context. Using CRISPR-CATCH, CRISPR interference and reporter assays, we confirm its presence on ecDNA, enhancer activity and essentiality for cancer cell fitness. These findings reveal that repetitive elements can be reactivated and co-opted as functional rather than inactive sequences on ecDNA, potentially driving oncogene expression and tumour evolution. Our study uncovers a mechanism by which ecDNA harnesses repetitive elements to shape cancer phenotypes, with implications for diagnosis and therapy.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: H.Y.C. is a cofounder of Accent Therapeutics, Boundless Bio, Cartography Biosciences and Orbital Therapeutics; he was an advisor of 10x Genomics, Arsenal Biosciences, Chroma Medicine and Spring Discovery until 15 December 2024. H.Y.C. is an employee and stockholder of Amgen as of 16 December 2024. M.G.J. is a consultant and holds equity in Tahoe Therapeutics. P.S.M. is a co-founder and advisor of Boundless Bio. J.D.B. is a founder and director of CDI Labs, Inc.; a founder of and consultant to Opentrons LabWorks/Neochromosome, Inc.; and serves or served on the scientific advisory boards of the following: CZ Biohub New York, LLC; Logomix, Inc.; Modern Meadow, Inc.; Rome Therapeutics, Inc.; Sangamo, Inc.; Tessera Therapeutics, Inc.; and the Wyss Institute. V.B. is a cofounder, serves on the scientific advisory board of Boundless Bio and Abterra and holds equity in both companies. Q.S. is an employee and stockholder of Amgen as of 20 February 2025. K.K. is an employee and stockholder of Amgen as of 15 September 2025. The other authors declare no competing interests.
Figures
Update of
-
Enhancer activation from transposable elements in extrachromosomal DNA.bioRxiv [Preprint]. 2025 Sep 8:2024.09.04.611262. doi: 10.1101/2024.09.04.611262. bioRxiv. 2025. Update in: Nat Cell Biol. 2025 Nov;27(11):1914-1924. doi: 10.1038/s41556-025-01788-6. PMID: 39282372 Free PMC article. Updated. Preprint.
References
-
- Wahl, G. M. The importance of circular DNA in mammalian gene amplification. Cancer Res.49, 1333–1340 (1989). - PubMed
MeSH terms
Substances
Grants and funding
- K99 CA286968/CA/NCI NIH HHS/United States
- K99CA286968/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- F99 CA274692/CA/NCI NIH HHS/United States
- DP5 OD037361/OD/NIH HHS/United States
- U24 CA264379/CA/NCI NIH HHS/United States
- K00 CA274692/CA/NCI NIH HHS/United States
- DGE-1656518/National Science Foundation (NSF)
- U01 DK127419/DK/NIDDK NIH HHS/United States
- EF2022182/National Science Foundation (NSF)
- OT2 CA278635/CA/NCI NIH HHS/United States
- F99CA274692/Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention)
- DP5OD037361/U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)
- R01 GM114362/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
